Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Overexpressed oncogenic proteins can become immunogenic, presenting potential vaccine targets.
• Colorectal cancer (CRC) associated proteins, elevated in incidence and linked to poor prognosis, were investigated as vaccine antigens.
• The study explored the efficacy of targeting these proteins to inhibit intestinal tumor development in mouse models.

Purpose of the Study:

• To evaluate overexpressed colorectal cancer-associated proteins as potential vaccine antigens.
• To determine if vaccines targeting these proteins can inhibit intestinal tumor development.
• To assess the immunogenicity and anti-tumor effects of peptide vaccines in preclinical models.

Main Methods:

• Humoral immunity assessed via ELISA; epitope identification using web algorithms.
• T-cell responses evaluated using IFN-gamma ELISPOT from human peripheral blood mononuclear cells.
• Peptide vaccines, homologous between mouse and human, were tested for immunogenicity and in vivo tumor challenge in AOM-induced and APC Min mouse models.

Main Results:

• Elevated serum IgG for CDC25B, COX2, RCAS1, and FASCIN1 in colorectal cancer patients.
• Successful generation of peptide and protein-specific T-cells from human lymphocytes.
• Vaccination with CDC25B and COX2 peptides significantly inhibited tumor growth and reduced tumor incidence in multiple mouse models, with 50% tumor-free rates in prophylactic settings.

Conclusions:

• Immunization with CDC25B and COX2 epitopes demonstrated consistent suppression of tumor development across evaluated models.
• These findings support the development of multi-antigen vaccines for colorectal cancer treatment and prevention.